08:00 | Registration |
|
Epigenetics in Disease | Session Sponsors |
| |
09:30 | Discovery of SDC2 Gene as a Methylation Biomarker and Utility Test in Serum-DNA for the Earlier Detection of Colorectal Cancer
Sungwhan An, CEO, Genomictree Inc, Korea South
With an increase in the global incidence of colorectal cancer there is a heightened need for the development of a convenient and high-quality non-invasive screening tests. Widespread use of colonoscopic screening has been limited by cost and low compliance. In the present study the outcome of detecting early stage tumors with SDC2 methylation test in serum DNA is promising enough for this test to be possibly a simple and robust tool to detect more cancers at the stage where treatment outcomes are excellent. |
10:00 | Genomic Analyses of Hormone Signaling and Gene Regulation
Edwin Cheung, Assistant Professor, Genome Institute of Singapore, Singapore
In my talk, I will show how my lab has applied novel high-throughput sequencing technologies to elucidate the chromatin organization of cancer cells upon hormone signaling, as well as the identification and characterization of novel factors required for nuclear hormone receptor transcriptional activity. |
10:30 | Coffee Break and Networking in the Exhibition Hall |
11:15 | CANCELLED - Epigenetic Disruption of Cell Signaling Regulation in Human Cancers
Qian Tao, Professor, The Chinese University of Hong Kong, Hong Kong
Summary to be Confirmed |
11:45 | Molecular Biologic Substaging of Gastric Cancer
Youg-Min Huh, Professor, Yonsei University, Korea South
The TMN staging system by integrating molecular information would be classified by patient’s genomic trait, and thereby facilitate the biologically tailored treatment according to the unique biology of tumor. |
12:15 | Lunch and Networking in the Exhibition Hall |
13:30 | Poster Viewing Session |
|
Applications of RNAi and Epigenetics in Diagnostics & Therapeutics |
| |
14:15 | SAMiRNA RNAi Nanoparticle Prodrug Technology
Jeiwook Chae, Director of RNAi, Bioneer, Korea South
Topics of discussion include SAMiRNA’s flexibility to incorporate siRNA sequences against any disease target, as well as enhancement of its therapeutic potential as a delivery platform through the use of cell-type specific targeting ligands. These data suggest that SAMiRNA is the most unique and singularly effective RNAi prodrug system developed to date. Using this novel RNAi prodrug technology, Bioneer is currently advancing clinical development of pipeline programs in previously non-druggable diseases, including cancer and COPD, through partnerships with major global pharmaceutical companies. |
14:45 |  | Keynote Presentation Chromatin Dynamics and Epigenetic Regulation in Cancer
Sung Hee Baek, Associate Professor, Seoul National University, Korea South
In this presentation, I will discuss our continued efforts to decipher epigenetic regulatory mechanism of new tumor and metastasis suppressor genes and their coregulators. I will introduce newly identified signaling crosstalk regulated by protein modification and address their roles in cancer. |
|
15:15 | Coffee Break and Networking in the Exhibition Hall |
16:00 | The Worldwide Market for MicroRNA and Epigenetics: Research, Diagnostics, and Therapeutics
Enal Razvi, Managing Director, Select Biosciences Inc, United States of America
Select Biosciences industry tracking of the microRNA and Epigenetic fields has focused on qualitative and quantitative market trends based on primary market analyses. We have also conducted extensive analysis of all the publications in these fields which allow us to track the evolution of research trends in this interrelated spaces. These market analyses have been recently published in the Select Biosciences MicroRNAs and Epigenetics 2012 Market Reports, and in this presentation I will present a snapshot of the research trends in microRNAs and Epigenetics and frame them into their potential utility as biomarker classes for the future. |
16:45 | Drinks Reception |
